title: Defining risk status in the first-line treatment of metastatic renal cell carcinoma.
abstract: Targeted agents, such as sunitinib, have significantly improved the prognosis of patients with metastatic renal cell carcinoma (mRCC) and are now well-established treatment options for these patients. Several pre-treatment clinical features have been associated with shorter survival, and identification of these prognostic factors has led to the development of risk models, such as the Memorial Sloan-Kettering Cancer Center (MSKCC) model. These risk models can be used to stratify patients according to their risk status. The risk status of patients can have important implications for their response to different treatment strategies; therefore, risk models enable treatment to be tailored for individual patients. In the MSKCC model, patients are stratified into one of three groups according to defined risk factors: favourable, intermediate or poor risk. The MSKCC model is well established and has been used to stratify patients in many clinical studies with targeted agents. However, some studies have used modified criteria which can make it difficult to make direct comparisons between studies. This can have important implications when selecting the most appropriate treatment for individual patients. In this review the rationale for establishing risk status is discussed and the practical application of risk models to aid the selection of appropriate first-line treatments is examined. Additionally, the evidence supporting the use of targeted agents in patients with mRCC according to their risk status is reviewed.
authors.affiliation: Department of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria. manuela.schmidinger@meduniwien.ac.at
authors.forename: Manuela
authors.initials: M
authors.lastname: Schmidinger
authors.forename: Christoph C
authors.initials: CC
authors.lastname: Zielinski
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors
chemical_list: D016898:Interferon-alpha
references.citation: Cancer. 2008 Oct 1;113(7):1552-8
references.pmid: 18720362
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1061-8
references.pmid: 20100962
references.citation: Lancet Oncol. 2009 Aug;10(8):757-63
references.pmid: 19615940
references.citation: Urol Clin North Am. 2003 Nov;30(4):843-52
references.pmid: 14680319
references.citation: N Engl J Med. 1996 Sep 19;335(12):865-75
references.pmid: 8778606
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5794-9
references.pmid: 19826129
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5204-12
references.pmid: 18838713
references.citation: Cancer Treat Rev. 2009 May;35(3):297-307
references.pmid: 19249157
references.citation: World J Urol. 2005 Jul;23(3):175-9
references.pmid: 15726382
references.citation: J Natl Cancer Inst. 2007 Jan 3;99(1):81-3
references.pmid: 17202116
references.citation: N Engl J Med. 2007 May 31;356(22):2271-81
references.pmid: 17538086
references.citation: J Clin Oncol. 2002 Jan 1;20(1):289-96
references.pmid: 11773181
references.citation: J Clin Oncol. 2009 Aug 1;27(22):3584-90
references.pmid: 19487381
references.citation: Lancet. 2007 Dec 22;370(9605):2103-11
references.pmid: 18156031
references.citation: Eur Urol. 2008 May;53(5):917-30
references.pmid: 18054825
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: J Clin Oncol. 1994 Jan;12(1):206-12
references.pmid: 8270978
references.citation: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references.pmid: 15761078
references.citation: Ann Oncol. 2009 May;20 Suppl 1:i7-12
references.pmid: 19430007
references.citation: Ann Oncol. 2007 Mar;18(3):581-92
references.pmid: 17287242
references.citation: J Clin Oncol. 2008 Nov 20;26(33):5422-8
references.pmid: 18936475
references.citation: Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001425
references.pmid: 15674877
references.citation: Cancer. 2010 Mar 1;116(5):1272-80
references.pmid: 20082451
references.citation: J Natl Compr Canc Netw. 2009 Jun;7(6):618-30
references.pmid: 19555584
references.citation: Lancet. 2008 Aug 9;372(9637):449-56
references.pmid: 18653228
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530
references.citation: Cancer Treat Rev. 2010 Feb;36(1):16-23
references.pmid: 19819078